Jianrong Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jianrong Chen has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Xu Zhou
Evidence-based Medicine Research Center, Jiangxi University of Chinese Medicine, Nanchang, China
6 shared publications Qing Ren
Department of Orthopedics and Traumatology, The University of Hong Kong, Hong Kong, China
2 shared publications- Qing Ren
School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China
2 shared publications Qingni Wu
Evidence-Based Medicine Research Center, Jiangxi University of Traditional Chinese Medicine, Nanchang, China
2 shared publicationsWeifeng Zhu
Evidence-Based Medicine Research Center, Jiangxi University of Traditional Chinese Medicine, Nanchang, China
2 shared publicationsYanping Wang
Evidence-Based Medicine Research Center, Jiangxi University of Traditional Chinese Medicine, Nanchang, China
2 shared publications
Latest Publications
- 21 May 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 369, 121891
Roles and mechanisms of Pueraria lobata radix in metabolic dysfunction-associated steatotic liver disease
- 21 May 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 369, 121891
Roles and mechanisms of Pueraria lobata radix in metabolic dysfunction-associated steatotic liver disease
- Open Access
- 16 September 2025
- Published by Bioscientifica in Endocrine Connections
- Vol. 14 (10)
tsRNA-25172 inhibits aldosterone secretion in aldosterone-producing adenomas
The pathophysiology of aldosterone-producing adenomas (APAs) is characterized by aldosterone hypersecretion. Transfer RNA-derived small RNAs (tsRNAs) are novel non-coding RNAs, which are involved in multiple biological processes. However, the role of tsRNAs in aldosterone synthesis and APAs remains poorly understood. Herein, immunohistochemistry was employed to assess the expression levels of aldosterone synthase CYP11B2 in APA patients. The differentially expressed miRNAs, piRNAs, and tsRNAs between adrenocortical adenomas (ACAs) and normal tissues were identified using small RNA sequencing data. The regulatory role of tsRNA-25172 on aldosterone synthesis in NCI-H295R cells was evaluated by qRT-PCR, CCK-8, and ELISA. We observed an abnormal increase in CYP11B2 expression in APA tissues. A total of 18 differentially expressed miRNAs, 5 differentially expressed piRNAs, and 159 differentially expressed tsRNAs were identified between ACA and normal tissues. Enrichment analysis revealed that dysregulated small RNAs were predominantly associated with cell adhesion, intracellular signal transduction, calcium signaling, and Wnt signaling pathways, leading to the identification of an ER-related gene, TGM2. tsRNA-25172 and tsRNA-25173 were downregulated in the ACA group. tsRNA-25172 mimics significantly inhibited the levels of aldosterone and cortisol in NCI-H295R cells. In contrast, tsRNA-25173 did not exhibit a notable effect. Moreover, overexpressed tsRNA-25172 markedly inhibited CYP11B2 and its target gene TGM2. Our findings reveal a pivotal role for tsRNA in APAs, potentially offering a novel exploratory approach and therapeutic target for the pathogenesis of APAs.
- 16 September 2025
- Published by Bioscientifica in Endocrine Connections
- Vol. 14 (10)
Open AccesstsRNA-25172 inhibits aldosterone secretion in aldosterone-producing adenomas
The pathophysiology of aldosterone-producing adenomas (APAs) is characterized by aldosterone hypersecretion. Transfer RNA-derived small RNAs (tsRNAs) are novel non-coding RNAs, which are involved in multiple biological processes. However, the role of tsRNAs in aldosterone synthesis and APAs remains poorly understood. Herein, immunohistochemistry was employed to assess the expression levels of aldosterone synthase CYP11B2 in APA patients. The differentially expressed miRNAs, piRNAs, and tsRNAs between adrenocortical adenomas (ACAs) and normal tissues were identified using small RNA sequencing data. The regulatory role of tsRNA-25172 on aldosterone synthesis in NCI-H295R cells was evaluated by qRT-PCR, CCK-8, and ELISA. We observed an abnormal increase in CYP11B2 expression in APA tissues. A total of 18 differentially expressed miRNAs, 5 differentially expressed piRNAs, and 159 differentially expressed tsRNAs were identified between ACA and normal tissues. Enrichment analysis revealed that dysregulated small RNAs were predominantly associated with cell adhesion, intracellular signal transduction, calcium signaling, and Wnt signaling pathways, leading to the identification of an ER-related gene, TGM2. tsRNA-25172 and tsRNA-25173 were downregulated in the ACA group. tsRNA-25172 mimics significantly inhibited the levels of aldosterone and cortisol in NCI-H295R cells. In contrast, tsRNA-25173 did not exhibit a notable effect. Moreover, overexpressed tsRNA-25172 markedly inhibited CYP11B2 and its target gene TGM2. Our findings reveal a pivotal role for tsRNA in APAs, potentially offering a novel exploratory approach and therapeutic target for the pathogenesis of APAs.
- 7 June 2024
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 333, 118429
Safety of medicinal and edible herbs from fruit sources for human consumption: A systematic review
- 7 June 2024
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 333, 118429
Safety of medicinal and edible herbs from fruit sources for human consumption: A systematic review
- 19 September 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (1) , 3-15
Role of the tripartite motif‐containing ( TRIM) family of proteins in insulin resistance and related disorders
Emerging evidence suggests that the ubiquitin‐mediated degradation of insulin‐signalling‐related proteins may be involved in the development of insulin resistance and its related disorders. Tripartite motif‐containing (TRIM) proteins, a superfamily belonging to the E3 ubiquitin ligases, are capable of controlling protein levels and function by ubiquitination, which is essential for the modulation of insulin sensitivity. Recent research has indicated that some of these TRIMs act as key regulatory factors of metabolic disorders such as type 2 diabetes mellitus, obesity, nonalcoholic fatty liver disease, and atherosclerosis. This review provides a comprehensive overview of the latest evidence linking TRIMs to the regulation of insulin resistance and its related disorders, their roles in regulating multiple signalling pathways or cellular processes, such as insulin signalling pathways, peroxisome proliferator‐activated receptor signalling pathways, glucose and lipid metabolism, the inflammatory response, and cell cycle control, as well as recent advances in the development of TRIM‐targeted drugs.
- 19 September 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (1) , 3-15
Role of the tripartite motif‐containing ( TRIM) family of proteins in insulin resistance and related disorders
Emerging evidence suggests that the ubiquitin‐mediated degradation of insulin‐signalling‐related proteins may be involved in the development of insulin resistance and its related disorders. Tripartite motif‐containing (TRIM) proteins, a superfamily belonging to the E3 ubiquitin ligases, are capable of controlling protein levels and function by ubiquitination, which is essential for the modulation of insulin sensitivity. Recent research has indicated that some of these TRIMs act as key regulatory factors of metabolic disorders such as type 2 diabetes mellitus, obesity, nonalcoholic fatty liver disease, and atherosclerosis. This review provides a comprehensive overview of the latest evidence linking TRIMs to the regulation of insulin resistance and its related disorders, their roles in regulating multiple signalling pathways or cellular processes, such as insulin signalling pathways, peroxisome proliferator‐activated receptor signalling pathways, glucose and lipid metabolism, the inflammatory response, and cell cycle control, as well as recent advances in the development of TRIM‐targeted drugs.
- 25 January 2021
- Published by S. Karger AG in Complementary Medicine Research
- Vol. 28 (5) , 435-445
Moxibustion for Essential Hypertension and Hypertensive Symptoms: A Systematic Review of 18 Randomized Controlled Trials
Introduction: This systematic review aims to update the evidence for moxibustion for essential hypertension. Methods: Randomized controlled trials (RCTs) comparing moxibustion versus lifestyle intervention or moxibustion plus antihypertensive drugs versus antihypertensive drugs alone were searched in 9 databases up to March 29, 2020. In meta-analyses, mean difference (MD) and proportional odds ratio (pOR) with 95% confidence intervals (CIs) was pooled for continuous and ordinal outcomes, respectively. Results: Eighteen RCTs were included, involving 1,460 patients. Moxibustion decreased systolic (MD –7.85 mm Hg, 95% CI –9.69 to –6.00, p < 0.00001, I2 = 46%) and diastolic (MD –4.09 mm Hg, 95% CI –5.45 to –2.73, p < 0.0001, I2 = 56%) blood pressures and improved the response to hypotensive treatment (pOR 2.37, 95% CI 1.49–3.75, p = 0.0003, I2 = 57%) significantly more than did the control treatment. Moxibustion also significantly relieved headache and dizziness but the effects changed to be statistically nonsignificant after excluding RCTs with a high risk of bias. Moxibustion did not significantly relieve insomnia and anxiety. No adverse events were reported. Conclusions: Based on the current low to moderate quality evidence, our study suggests that moxibustion may have effects on reducing blood pressure. The effects of moxibustion on typical hypertension symptoms and the long-term safety of moxibustion remain uncertain.
- 25 January 2021
- Published by S. Karger AG in Complementary Medicine Research
- Vol. 28 (5) , 435-445
Moxibustion for Essential Hypertension and Hypertensive Symptoms: A Systematic Review of 18 Randomized Controlled Trials
Introduction: This systematic review aims to update the evidence for moxibustion for essential hypertension. Methods: Randomized controlled trials (RCTs) comparing moxibustion versus lifestyle intervention or moxibustion plus antihypertensive drugs versus antihypertensive drugs alone were searched in 9 databases up to March 29, 2020. In meta-analyses, mean difference (MD) and proportional odds ratio (pOR) with 95% confidence intervals (CIs) was pooled for continuous and ordinal outcomes, respectively. Results: Eighteen RCTs were included, involving 1,460 patients. Moxibustion decreased systolic (MD –7.85 mm Hg, 95% CI –9.69 to –6.00, p < 0.00001, I2 = 46%) and diastolic (MD –4.09 mm Hg, 95% CI –5.45 to –2.73, p < 0.0001, I2 = 56%) blood pressures and improved the response to hypotensive treatment (pOR 2.37, 95% CI 1.49–3.75, p = 0.0003, I2 = 57%) significantly more than did the control treatment. Moxibustion also significantly relieved headache and dizziness but the effects changed to be statistically nonsignificant after excluding RCTs with a high risk of bias. Moxibustion did not significantly relieve insomnia and anxiety. No adverse events were reported. Conclusions: Based on the current low to moderate quality evidence, our study suggests that moxibustion may have effects on reducing blood pressure. The effects of moxibustion on typical hypertension symptoms and the long-term safety of moxibustion remain uncertain.
- Open Access
- 1 January 2020
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2020 (1) , 6128673
Moxibustion as an Adjuvant Therapy for Chronic Kidney Disease: A Systematic Review and Meta‐Analysis of 23 Randomized Controlled Trials
Objective. This systematic review aims to investigate the efficacy and safety of moxibustion for chronic kidney disease (CKD). Methods. Nine databases were searched to identify relevant evidence up to March 8, 2020. Randomized controlled trials (RCTs) that tested moxibustion + basic treatments versus basic treatments alone for patients with CKD and reported, at least, one of the outcomes of interest were included. In the meta‐analyses, the mean differences (MDs) and 95% confidence intervals (CIs) were used to measure the effect size. Results. Twenty‐three RCTs (n = 1571) with a moderate to high risk of bias were included. The pooled estimates showed that compared with the controls, patients after moxibustion had a significant reduction in serum creatinine (MD −17.34 μmol/L, 95% CI −28.44 to −6.23; I2 = 87%), 24‐hour urine protein excretion (MD −0.75 g/h, 95% CI −1.07 to −0.42; I2 = 84%), and blood urea nitrogen (MD −0.63 mmol/L, 95% CI −1.09 to −0.18; I2 = 37%) and a significant improvement in the quality of life (MD 10.18, 95% CI 3.67 to 16.69; I2 = 57%). Moxibustion did not show a significant effect on the estimated glomerular filtration rate (eGFR), creatinine clearance, or hemoglobin. The subgroup analyses showed that a longer course of moxibustion (>8 weeks) and indirect moxibustion had a greater effect on reducing serum creatinine. The effect of moxibustion on blood urea nitrogen changed to be nonsignificant after excluding RCTs with a high risk of bias (MD −0.96 mmol/L, 95% CI −2.96 to 1.03). Only one adverse event of burn was reported. Conclusions. This systematic review suggests that, as an adjuvant therapy, moxibustion may improve serum creatinine, urinary protein excretion, blood urea nitrogen, and quality of life in patients with CKD. Moxibustion may not have effects on eGFR, creatinine clearance, or hemoglobin. The quality of evidence is weakened by the limitations of risk of bias, heterogeneity, and imprecision.
- 1 January 2020
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2020 (1) , 6128673
Open AccessMoxibustion as an Adjuvant Therapy for Chronic Kidney Disease: A Systematic Review and Meta‐Analysis of 23 Randomized Controlled Trials
Objective. This systematic review aims to investigate the efficacy and safety of moxibustion for chronic kidney disease (CKD). Methods. Nine databases were searched to identify relevant evidence up to March 8, 2020. Randomized controlled trials (RCTs) that tested moxibustion + basic treatments versus basic treatments alone for patients with CKD and reported, at least, one of the outcomes of interest were included. In the meta‐analyses, the mean differences (MDs) and 95% confidence intervals (CIs) were used to measure the effect size. Results. Twenty‐three RCTs (n = 1571) with a moderate to high risk of bias were included. The pooled estimates showed that compared with the controls, patients after moxibustion had a significant reduction in serum creatinine (MD −17.34 μmol/L, 95% CI −28.44 to −6.23; I2 = 87%), 24‐hour urine protein excretion (MD −0.75 g/h, 95% CI −1.07 to −0.42; I2 = 84%), and blood urea nitrogen (MD −0.63 mmol/L, 95% CI −1.09 to −0.18; I2 = 37%) and a significant improvement in the quality of life (MD 10.18, 95% CI 3.67 to 16.69; I2 = 57%). Moxibustion did not show a significant effect on the estimated glomerular filtration rate (eGFR), creatinine clearance, or hemoglobin. The subgroup analyses showed that a longer course of moxibustion (>8 weeks) and indirect moxibustion had a greater effect on reducing serum creatinine. The effect of moxibustion on blood urea nitrogen changed to be nonsignificant after excluding RCTs with a high risk of bias (MD −0.96 mmol/L, 95% CI −2.96 to 1.03). Only one adverse event of burn was reported. Conclusions. This systematic review suggests that, as an adjuvant therapy, moxibustion may improve serum creatinine, urinary protein excretion, blood urea nitrogen, and quality of life in patients with CKD. Moxibustion may not have effects on eGFR, creatinine clearance, or hemoglobin. The quality of evidence is weakened by the limitations of risk of bias, heterogeneity, and imprecision.
- Open Access
- 1 January 2020
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2020 (1)
Quality and Specific Concerns of Clinical Guidelines for Integrated Chinese and Western Medicine: A Critical Appraisal
Objective. This study aimed to investigate the methodological quality of clinical guidelines (CGs) for integrated Chinese and Western medicine (ICWM) to inform clinical practice and guideline development. Methods. We searched PubMed, EMBASE, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, Wanfang Data, VIP, five guideline databases, and four online book malls to identify ICWM CGs published up to January 11, 2019. Four independent appraisers assessed the quality of CGs using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument and evaluated six specific concerns for ICWM. The standardized scores were calculated for the individual AGREE II domains. Results. Sixty‐two ICWM CGs were included. The median standardized scores in the six domains of AGREE II were 65% in scope and purpose, 46% in clarity of presentation, 26% in applicability, 24% in stakeholder involvement, 15% in rigor of development, and 0% in editorial independence. The quality of ICWM CGs was significantly associated with the publication year (higher quality for CGs published after 2014) and the development method (higher quality for evidence‐based CGs). Only one ICWM CG obtained a direct recommendation for use, and 14 could be recommended for use after modifications. The intra‐appraiser consistency of the AGREE II appraisal was good (mean intraclass correlation coefficient range, 0.813–0.998). ICWM CGs also lacked a systematic search of ancient traditional Chinese medicine (TCM) classics (40.3%), conversion of TCM recommendations from ancient Chinese to the vernacular (14.5%), a discussion of interactions between TCM and Western medicine (27.4%), and rankings of different ICWM choices (0%). Conclusions. Although an improvement after 2014 occurred, the current 64 ICWM CGs are generally of poor methodological quality. Only 15 ICWM CGs can be recommended for use directly or with modifications. As the key distinctions from Western/Chinese medicine CGs, the ICWM‐specific recommendations are also insufficient for the ICWM CGs, especially for interactions between TCM and Western medicine and rankings of different ICWM choices. Study Registration. This study has been registered at PROSPERO (no. CRD42018095767).
- 1 January 2020
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2020 (1)
Open AccessQuality and Specific Concerns of Clinical Guidelines for Integrated Chinese and Western Medicine: A Critical Appraisal
Objective. This study aimed to investigate the methodological quality of clinical guidelines (CGs) for integrated Chinese and Western medicine (ICWM) to inform clinical practice and guideline development. Methods. We searched PubMed, EMBASE, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, Wanfang Data, VIP, five guideline databases, and four online book malls to identify ICWM CGs published up to January 11, 2019. Four independent appraisers assessed the quality of CGs using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument and evaluated six specific concerns for ICWM. The standardized scores were calculated for the individual AGREE II domains. Results. Sixty‐two ICWM CGs were included. The median standardized scores in the six domains of AGREE II were 65% in scope and purpose, 46% in clarity of presentation, 26% in applicability, 24% in stakeholder involvement, 15% in rigor of development, and 0% in editorial independence. The quality of ICWM CGs was significantly associated with the publication year (higher quality for CGs published after 2014) and the development method (higher quality for evidence‐based CGs). Only one ICWM CG obtained a direct recommendation for use, and 14 could be recommended for use after modifications. The intra‐appraiser consistency of the AGREE II appraisal was good (mean intraclass correlation coefficient range, 0.813–0.998). ICWM CGs also lacked a systematic search of ancient traditional Chinese medicine (TCM) classics (40.3%), conversion of TCM recommendations from ancient Chinese to the vernacular (14.5%), a discussion of interactions between TCM and Western medicine (27.4%), and rankings of different ICWM choices (0%). Conclusions. Although an improvement after 2014 occurred, the current 64 ICWM CGs are generally of poor methodological quality. Only 15 ICWM CGs can be recommended for use directly or with modifications. As the key distinctions from Western/Chinese medicine CGs, the ICWM‐specific recommendations are also insufficient for the ICWM CGs, especially for interactions between TCM and Western medicine and rankings of different ICWM choices. Study Registration. This study has been registered at PROSPERO (no. CRD42018095767).
- Open Access
- 12 December 2019
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 19 (1) , 1-14
Oral and injectable Marsdenia tenacissima extract (MTE) as adjuvant therapy to chemotherapy for gastric cancer: a systematic review
Background: Marsdenia tenacissima extract (MTE) is a phytochemical widely used as complementary therapy in cancer care. This systematic review was conducted to investigate the anticancer and detoxification effects of MTE, as an adjuvant therapy to chemotherapy, for treating gastric cancer. Methods: Ten databases were searched to identify randomized controlled trials (RCTs) comparing oral or injectable MTE plus chemotherapy versus chemotherapy alone for treating gastric cancer up to May 1, 2019. In meta-analyses, proportional odds ratios (PORs) with 95% confidence intervals (CIs) were pooled for the ordinal outcomes using the generalized linear model, and risk ratios (RRs) with 95% CIs were pooled for dichotomous outcomes using the Mantel-Haenszel method. Results: Seventeen RCTs with 1329 individuals were included, with a moderate to high risk of selection and performance bias. Compared to chemotherapy alone, MTE adjuvant therapy significantly improved the response to anticancer treatment (POR 2.01, 95% CI 1.60–2.53) and patients’ performance status (POR 3.15, 95% CI 2.22–4.48) and reduce the incidences of chemotherapy-induced leukopenia (RR 0.66, 95% CI 0.56–0.78), thrombocytopenia (RR 0.64, 95% CI 0.48–0.86), anemia (RR 0.89, 95% CI 0.72–1.10), nausea/vomiting (RR 0.79, 95% CI 0.69–0.91), hepatic injury (RR 0.77, 95% CI 0.61–0.96), and peripheral neurotoxicity (RR 0.77, 95% CI 0.59–1.01). However, MTE did not significantly alleviate anemia, diarrhea, constipation, kidney injury, and oral mucosal lesions after chemotherapy. Incidence of nausea/vomiting was lower in patients receiving oral MTE than those receiving injectable MTE (RR 0.47 vs. 0.82, interaction P = 0.04). Heterogeneity was generally low among these outcomes. Three out of five RCTs that reported survival data supported the effects of MTE for prolonging progression-free and/or overall survival. No studies reported safety outcomes of MTE. Conclusions: The current evidence with limitations of risk of selection and performance bias suggests that MTE, as an adjuvant therapy to chemotherapy, is effective for inhibiting cancer growth and reducing incidences of multiple chemotherapy side effects. Oral MTE may be a better choice. Uncertainty remains regarding the effects of MTE on survival endpoints and the subgroup differences between acute and chronic use of MTE and between different chemotherapy regimens.
- 12 December 2019
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 19 (1) , 1-14
Open AccessOral and injectable Marsdenia tenacissima extract (MTE) as adjuvant therapy to chemotherapy for gastric cancer: a systematic review
Background: Marsdenia tenacissima extract (MTE) is a phytochemical widely used as complementary therapy in cancer care. This systematic review was conducted to investigate the anticancer and detoxification effects of MTE, as an adjuvant therapy to chemotherapy, for treating gastric cancer. Methods: Ten databases were searched to identify randomized controlled trials (RCTs) comparing oral or injectable MTE plus chemotherapy versus chemotherapy alone for treating gastric cancer up to May 1, 2019. In meta-analyses, proportional odds ratios (PORs) with 95% confidence intervals (CIs) were pooled for the ordinal outcomes using the generalized linear model, and risk ratios (RRs) with 95% CIs were pooled for dichotomous outcomes using the Mantel-Haenszel method. Results: Seventeen RCTs with 1329 individuals were included, with a moderate to high risk of selection and performance bias. Compared to chemotherapy alone, MTE adjuvant therapy significantly improved the response to anticancer treatment (POR 2.01, 95% CI 1.60–2.53) and patients’ performance status (POR 3.15, 95% CI 2.22–4.48) and reduce the incidences of chemotherapy-induced leukopenia (RR 0.66, 95% CI 0.56–0.78), thrombocytopenia (RR 0.64, 95% CI 0.48–0.86), anemia (RR 0.89, 95% CI 0.72–1.10), nausea/vomiting (RR 0.79, 95% CI 0.69–0.91), hepatic injury (RR 0.77, 95% CI 0.61–0.96), and peripheral neurotoxicity (RR 0.77, 95% CI 0.59–1.01). However, MTE did not significantly alleviate anemia, diarrhea, constipation, kidney injury, and oral mucosal lesions after chemotherapy. Incidence of nausea/vomiting was lower in patients receiving oral MTE than those receiving injectable MTE (RR 0.47 vs. 0.82, interaction P = 0.04). Heterogeneity was generally low among these outcomes. Three out of five RCTs that reported survival data supported the effects of MTE for prolonging progression-free and/or overall survival. No studies reported safety outcomes of MTE. Conclusions: The current evidence with limitations of risk of selection and performance bias suggests that MTE, as an adjuvant therapy to chemotherapy, is effective for inhibiting cancer growth and reducing incidences of multiple chemotherapy side effects. Oral MTE may be a better choice. Uncertainty remains regarding the effects of MTE on survival endpoints and the subgroup differences between acute and chronic use of MTE and between different chemotherapy regimens.